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Abstract 
Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare neurodegenerative disorder in which 
accumulation of a pathogenic isoform of prion protein (PrPSc) induces neuronal damage 
with distinct pathologic features. The prognosis of sCJD is devastating: rapid clinical 
decline is followed by death generally within months after onset of symptoms. The 
classic clinical manifestations of sCJD are rapidly progressing dementia, myoclonus, and 
ataxia. However, the spectrum of clinical features can vary considerably. We describe a 
definite, neuropathologically verified sCJD in a 67-year-old woman who initially 
presented with progressive stroke-like symptoms: left-sided hemiparesis and ataxia 
within a few days. The initial brain magnetic resonance imaging (MRI) showed bilateral 
cortical hyperintensity on diffusion-weighted sequences (DWI) resembling multiple 
ischemic lesions. Despite anticoagulation with low-molecular-weight heparin, the 
patient deteriorated rapidly, became dysphagic and bedridden with myoclonic jerks on 
her left side extremities correlating with intermittent high-amplitude epileptiform 
discharges on electroencephalography (EEG). Basal ganglia hyperintense signal changes 
in addition to cortical ribboning were seen in DWI images of a follow-up MRI. Repeated 
EEG recordings showed an evolution to periodic sharp wave complexes. Protein 14-3-3 
was positive in her cerebrospinal fluid specimen, in addition to an abnormally high total 
tau level. In the terminal stage the patient was in an akinetic, mutistic state with 
deteriorating consciousness. She died 19 days after admission to the hospital. 
Neuropathologic investigation corroborated the clinical diagnosis of sCJD with 
spongiform degeneration and immunohistochemical demonstration of the deposition of 
pathologic PrPSc.  
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Introduction 
Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare and invariably fatal 
neurodegenerative disorder caused by accumulation of a misfolded, protease-resistant, 
and pathogenic form of prion protein (PrP
Sc), which possibly evolves from its normal 
cellular precursor (PrP
C) either through spontaneous post-translational conformational 
change (random misfolding) or due to mutation of the prion protein gene (PRNP) [1]. 
What seems to follow is a self-perpetuating conformational conversion and propagation 
of PrP
Sc infectivity throughout the brain, although the exact mechanisms of spreading 
remain unclear [2]. No inflammatory or immunologic reaction is evoked. The physiologic 
function of PrP
C, a membrane-bound sialoglycoprotein found predominantly in the 
brain, is unknown. 
sCJD represents about 85% of human prion disease cases [3]. Other, less common 
types include familial (inherited) and acquired forms. PrP
Sc is able to replicate, is 
potentially transmissible, and can (like in the case of variant CJD) cross the species barrier 
[1]. Transmitted prion diseases are thought to have very long incubation periods of up to 
several decades. 
The clinical presentation of sCJD can be highly variable and significant overlap exists 
with other central nervous system (CNS) disorders. We describe a neuropathologically 
verified sCJD in a patient who initially presented with progressive stroke-like symptoms. 
Case Report 
A 67-year-old woman had previously been healthy. She was a non-smoker and had normal plasma 
glucose and lipid levels. She had no history of substance abuse, blood transfusions, major surgical 
procedures, or symptoms suggesting cardiac or cerebrovascular disease. Her blood pressure (BP), 
however, had been abnormally high (up to 205/105 mm Hg) and had been followed on a regular basis 
during the previous 4 months. There was no family history of rapidly progressing dementia or 
movement disorders leading to death. 
The patient presented at the Emergency Ward of a regional hospital due to progressing symptoms 
(day 1). She had experienced fatigue and loss of energy for approximately 3 months, and more recently 
(for 3–4 weeks) insomnia, memory impairment, sluggish speech, tinnitus, strange facial discomfort, 
progressing balance and gait difficulties and clumsiness of the left limbs with abnormal sensations and 
jerky movements in the left upper limb. There had been a rapid exacerbation of motor symptoms over a 
3-day period prior to admission. Upon arrival, unsteady gait with gait apraxia was observed, and she 
was only able to walk with assistance. Left finger-nose ataxia and dysdiadochokinesis, as well as 
weakness of the lower part of the left face were observed, the knee reflex being slightly brisker 
ipsilaterally. Visual or positive motor symptoms were absent and there were no other relevant findings 
in neurologic exam. Brain computed tomography scan, chest X-ray, and the results of routine blood 
tests were unremarkable, and there were no clinically significant ECG findings. BP was high (165–
205/95–105 mm Hg). On day 2 the patient was referred to the Emergency Department of Helsinki 
University Central Hospital for neurological evaluation. The attending neurologist observed mild 
dysartria with left upper motor neuron facial paresis, left hemiparesis and ataxia (upper limb 
predominating). BP was 190/90–95 mm Hg with a heart rate of 85/min. Brain magnetic resonance 
imaging (MRI) with MR angiography of the intracranial and cervical arteries was performed within 2 h 
of admission. T2-weighted images showed mild leucoaraiosis in the subcortical white matter. More 
distinctively, diffusion-weighted imaging (DWI) showed multiple parenchymal hyperintensities in both 
cerebral hemispheres (parietal, temporal, and occipital lobes bilaterally with the right side more 
affected). MR angiography images were technically suboptimal due to movement artifacts, but no 
obvious arterial pathology was observable. The initial working diagnosis was ischemic stroke based on 
clinical features (high BP, highly asymmetric, rapidly evolved motor symptoms) and imaging findings 
consistent with multifocal cerebral ischemia. Low-dose aspirin (100 mg) plus slow-release dipyridamole 
(200 mg twice daily) were initiated, the dosage of antihypertensive agent candesartan was increased (16 
mg once daily) and the patient was transferred to a neurological ward. On days 3–5 the patient  
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remained stable and her BP was reduced to normal levels. Echocardiography (day 3) demonstrated left-
sided cardiac hypertrophy consistent with chronic hypertensive heart disease, but there were no 
findings supporting a putative cerebral embolism with a cardiac source. A wide range of blood and 
urine tests were taken for hematologic, clinical chemistry, and serologic evaluation. Fasting plasma 
glucose (4.7–5.9 mM) and cholesterol (total 4.7 mM, LDL 2.4 mM) levels were in the normal range, and 
there were no other clinically relevant abnormal findings. 
On day 6 the patient became rapidly less alert, dysphagic with exacerbation of motor symptoms 
(weakness and ataxia) on the left side extremities. With the initial working diagnosis, progressive 
ischemic stroke was assumed and the patient was anticoagulated using subcutaneous low-molecular-
weight heparin (LMWH, dalteparin 7,000 IU twice daily) with anti-FXa activity monitoring. 
Antiplatelet therapy was discontinued. The first brain MRI re-scan was unsuccessful due to motor 
restlessness of the patient. At this point (day 8), mild intermittent myoclonic jerks in the left side limbs 
were observed with abnormal electroencephalography (EEG) showing diffuse slowing and sporadic, 
high-amplitude epileptiform discharges with partial periodicity, right-sided predominance, and clinical 
correlation with contralateral myoclonus. Clinical and EEG findings now evoked suspicion of a sCJD as 
a diagnostic alternative. The 1st MRI images (from day 2) were re-evaluated, leading to the conclusion 
that cortical hyperintense signal changes seen on DWIs (fig. 1) could also be explained by sCJD-related 
pathology. Myoclonic jerks were unresponsive to intravenous valproic acid (loading dose of 600 mg 
followed by 300 mg twice daily). On day 9 the patient had become bedridden and increasingly drowsy. 
Myoclonus was more frequent and of higher amplitude. Severe ataxia and motor paresis on the left side, 
paralysis of left conjugate gaze, and inattention of the left visual field (consistent with the right frontal 
and parietal lobe lesions, respectively) could be observed. DWI images of the 2nd MRI (day 10) showed 
widely distributed cortical signal hyperintensities (ribboning) in the right frontal (insular) cortex and 
parieto-occipital cortices bilaterally, the findings being less remarkable on the left side and less 
conspicuous than in the 1st MRI. DWI hyperintensities were detectable also in the basal ganglia, 
particularly in the caudate and the anterior parts of the lentiform nuclei, corroborating the 
neuroradiologic diagnosis of sCJD. 
With sCJD as the most likely diagnosis, the decision not to resuscitate and to withhold life-
sustaining treatment was made in good agreement with the patient’s family members. The LMWH 
dosage was reduced to thromboprophylaxis level (5,000 IU once daily), clonazepam (0.5 mg twice daily) 
was initiated to suppress myoclonus, and a nasogastric tube was inserted to secure enteral drug delivery 
and nutrition. A transdermal fentanyl patch (up to 50 μg/72 h) was introduced to provide pain relief. 
Cerebrospinal fluid (CSF, sampling on day 15) leukocyte and protein levels were in the normal 
range, as were the results of serologic tests for different microbial pathogens. Protein 14-3-3 was 
positive. CSF total tau level was markedly elevated (>1,200 pg/ml), whereas the concentration of 
phospho-tau (P-tau) was normal (38 pg/ml). The 2nd EEG (day 18) was typical for sCJD showing 
destruction of the background rhythms with distinctive periodic, synchronous, and generalized  
bi-/triphasic sharp-wave complexes (PSWCs) (fig. 2). 
From day 11 onward the patient showed a rapid clinical deterioration into an akinetic mutistic state. 
Myoclonic phenomena were less remarkable, and there was a general increase in spasticity. The patient 
became febrile, comatose, and developed episodes of apnea. She died 19 days after admission. 
Post-mortem neuropathologic examination was done. The CNS macroscopic findings were quite 
unremarkable and unspecific: there were no signs of cortical (hippocampal or other) atrophy or focal 
pathologic changes. Intracranial arteries were normal. However, the microscopic and 
immunohistochemical examinations were confirmatory for sCJD: spongiform degeneration with 
vacuolar change most prominent in the molecular layer of the cerebellum and, to a lesser extent, in 
neocortical areas, putamen, and thalamus. Neither florid (characteristic for variant CJD) nor Kuru 
plaques were detected. Immunohistochemistry showed protease-resistant PrP immunoreactivity, most 
clearly in the cerebellar cortex, but also in cortical and basal ganglia specimens. 
Discussion 
No therapeutic interventions exist that can alter the clinical course of sCJD [4]. 
Fortunately, this fatal disease is rare with an estimated worldwide incidence 
approximately one case per million per year [1, 2].  
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The diagnosis of sCJD is relatively straightforward when a patient with rapidly 
progressive dementia manifests myoclonus and PSWCs on EEG [3, 5]. Confusion and 
memory disturbance are the most common presenting features and practically all develop 
dementia at some stage [4]. Ataxia develops in up to 2 thirds [3]. The stroke-like 
symptoms in our patient (rapidly progressing hemiparesis and ataxia), however, 
substantiate the fact that sCJD can be a clinical chameleon [4] and the diagnosis 
challenging. Vague prodromal symptoms of fatigue, malaise, depression, decreased 
appetite, and sleep disturbances have been documented in about 1 third of the patients 
with sCJD [1, 6]. The disease may also present with focal cortical or lateralized syndromes 
[7] that mimic other CNS disorders (for example neurodegenerative, inflammatory, 
vascular, paraneoplastic, or metabolic) [4]. The classic features may be absent early on. 
Ataxia, for example, is the presenting symptom only in a minority [4]. In the later stages, 
however, characteristic symptoms usually become apparent, as they did in the present 
case. 
Brain MRI with DWI [8], assessment of 14-3-3 protein from CSF [9] and serial EEG 
recordings [10] should be integrated into the diagnostic workup of sCJD. DWI sequences 
demonstrate increased cortical and basal ganglia signal and are highly sensitive and 
specific for sCJD [8, 11]. PSWCs on EEG occur in about 2 thirds of patients with sCJD 
[10]. CSF protein 14-3-3 is a marker of neuronal death and can be detected in many CNS 
disorders, such as stroke, encephalitis, and paraneoplastic syndromes [1–3]. In sCJD it 
has been reported to have 80–90% sensitivity and 90% specificity for the diagnosis [12]. 
Characteristic MRI and EEG changes are commonly found only with repeated 
examination [1]. This was also the case in our patient whose EEG changed from 
unspecific to characteristic with pseudoperiodic paroxysms [4] in just 10 days. Our 
patient’s DWI findings were typical with cortical ribbon hyperintensities, a highly 
sensitive finding in sCJD [13]. The patient’s CSF protein 14-3-3 was positive, tau level was 
very high, whereas P-tau/total tau ratio was low. All these findings are in support of sCJD. 
There is class I evidence on dramatic increases in CSF total tau without similar increases 
in P-tau [12]. Finally, neuropathologic findings (essential for definite diagnosis) in the 
present case were typical for sCJD. 
Clinically atypical forms of sCJD are well recognized in the literature. The phenotypic 
variation seems to be due to differences in both the molecular and physicochemical 
structure of prion strains and polymorphism of the PRNP [6, 14]. Six subtypes of sCJD 
with different clinicopathologic features based on codon 129 polymorphism 
(methionine/valine) and PrP type have been proposed [14]. Sporadic CJD has also been 
classified into 5 different phenotypes which differ by several characteristics, for example 
age at disease onset, survival time, and diagnostic test results [15]. Neither PrP
Sc 
phenotyping nor PRNP sequencing were done in the present case. The age at onset of our 
patient (67 years) was quite typical for sCJD [5]. 
There were subtle hints towards the diagnosis of sCJD and against the cerebrovascular 
diagnosis already at the beginning of the acute stroke-like presentation of the left-sided 
motor paresis and ataxia. Firstly, there was a lack of major cerebrovascular risk factors 
besides hypertension and age of 67 years. Secondly, there was a 3-month prodromal phase 
of unspecific symptoms of fatigue and loss of energy. Even more atypical for ischemic 
stroke, there was a subacute 3–4-week period with a broad range of other, mostly non-
localizing symptoms. The symptoms of ischemic stroke usually evolve in minutes, more 
seldom do they progress over hours or days, with basilar artery thrombosis symptoms 
sometimes evolving over weeks with asymptomatic periods in between. Thirdly, even in 
the first head MRI, there were bilateral (although more prominent in the right  
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hemisphere) hyperintense lesions affecting multiple vascular regions. However, such a 
finding could also be attributed to cardiac embolization, and the basal ganglia 
hyperintense lesions typical for sCJD were lacking at that point. 
The stroke-like symptoms of the present case demonstrate the variability in the clinical 
presentation of sCJD. A high level of clinical suspicion may prove useful in obtaining 
early diagnosis and therefore avoiding costly and inefficient therapeutic strategies. 
 
 
 
 
 
Fig. 1. The 1st brain diffusion-weighted images of the Creutzfeldt-Jakob disease patient showing 
hyperintensity of the right insular cortex (a; arrow) and occipital cortices bilaterally (b; arrows). 
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Fig. 2. The repeated 2nd electroencephalography of the present case demonstrates periodic generalized 
bi/triphasic complexes typical for sporadic Creutzfeldt-Jakob disease. 
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